Atezolizumab in combination with carboplatin and etoposide for heavily treated small cell lung cancer

Atezolizumab was the first immune checkpoint inhibitor (ICI) to be introduced as a first‐line treatment option for extensive‐stage small cell lung cancer (ES‐SCLC), in combination with carboplatin and etoposide (CE) chemotherapy. However, SCLC treatment options after progression to first‐line chemot...

Descripción completa

Detalles Bibliográficos
Autores principales: Kataoka, Nobutaka, Kunimatsu, Yusuke, Tachibana, Yusuke, Sugimoto, Takumi, Sato, Izumi, Tani, Nozomi, Ogura, Yuri, Hirose, Kazuki, Takeda, Takayuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471014/
https://www.ncbi.nlm.nih.gov/pubmed/32706170
http://dx.doi.org/10.1111/1759-7714.13588

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471014/
https://www.ncbi.nlm.nih.gov/pubmed/32706170
http://dx.doi.org/10.1111/1759-7714.13588

Ejemplares similares